The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Books
  • Non-profit
  • Education
  • Sports
  • Automotive

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners
  • Tim Tebow to Headline BSI CORE Annual Summit, Bringing Nearly 400 Business Leaders Together at Bethlehem's SteelStacks

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • Pipeliners Tour Brings Appalachian Basin Rally to Western Pennsylvania
  • Gigasoft 2026 JavaScript Chart Comparison: ProEssentials, Highcharts, SciChart, LightningChart, ECharts
  • Experienced eXp Realty Agent Kerri Lawless Guides Buyers and Sellers Through Life's Next Chapters in St. Tammany Parish
  • Supreme Garage Door Repair Redirects Marketing Dollars Into North Texas Communities
  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
  • LATO AI Solidifies Future in Pittsburgh with North Shore Headquarters
  • Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
  • Nadi Plumbing Leads Charlotte in Private Fire Hydrant Services, Eyes Regional Expansion
  • Obsolete Industrial Expands Its Membership
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Four-Time Olympian Joetta Clark Diggs to Compete at World Masters Athletics Championships in Daegu
  • New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
  • The Alistair Apartments Reaches 95% Occupancy in Downtown Lancaster, PA
  • Food Journal Magazine Focuses Its Los Angeles Dining Coverage Across Three Editorial Verticals
  • Where Do Missouri Plane Crashes Really Happen? Not Where You'd Think
  • LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
  • Kellyn Endorses National Push to Expand Food is Medicine
  • LATO AI Automates Customer Communication to Help CSide Sports Academy and BAT 24 Nation Grow

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 1001
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 122
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
  • Nola Blue Records Announces New Album from Sherman Holmes
  • FDA Food Recall Notices After Outbreak Linked to 98 Hospitalizations: Practical Tips for Safer Grocery Shopping
  • The 'Tax Squeeze': Betsson's Record Quarter Previews the Economics of Finland's 2027 Casino Market
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
  • Colonial Nissan Helps Multiple Generations of the Community Find Their Next Vehicle

Similar on PennZone

  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access
  • ANSI BSR Upholds Appeal of AFDE Member Andrew Sulner, MSFS, JD, finding the AAFS Academy Standards Board (ASB) Violated ANSI Essential Requirements
  • StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
  • Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
  • When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us